28536535|t|Role of Intestinal LXRα in Regulating Post-prandial Lipid Excursion and Diet - Induced Hypercholesterolemia and Hepatic Lipid Accumulation
28536535|a|Post-prandial hyperlipidemia has emerged as a cardiovascular risk factor with limited therapeutic options. The Liver X receptors (Lxrs) are nuclear hormone receptors that regulate cholesterol elimination. Knowledge of their role in regulating the absorption and handling of dietary fats is incomplete. The purpose of this study was to determine the role of intestinal Lxrα in post-prandial intestinal lipid transport. Using Lxrα knockout (nr1h3(-/-)) and intestine - limited Lxrα over-expressing [Tg(fabp2a: EGFP - nr1h3)] zebrafish strains, we measured post-prandial lipid excursion with live imaging in larvae and physiological methods in adults. We also conducted a long-term high - cholesterol dietary challenge in adults to examine the chronic effect of modulating nr1h3 gene dose on the development of hypercholesterolemia and hepatic lipid accumulation. Over-expression of Lxrα in the intestine delays the transport of ingested lipids in larvae, while deletion of Lxrα increases the rate of lipid transport. Pre-treating wildtype larvae with the liver-sparing Lxr agonist hyodeoxycholic acid also delayed the rate of intestinal lipid transport in larvae. In adult males, deletion of Lxrα accelerates intestinal transport of ingested lipids. Adult females showed higher plasma Lipoprotein lipase (Lpl) activity compared to males, and lower post-gavage blood triacylglycerol (TAG) excursion. Despite the sexually dimorphic effect on acute intestinal lipid handling, Tg(fabp2a: EGFP - nr1h3) adults of both sexes are protected from high cholesterol diet (HCD)- induced hepatic lipid accumulation, while nr1h3(-/-) mutants are sensitive to the effects of HCD challenge. These data indicate that intestinal Lxr activity dampens the pace of intestinal lipid transport cell-autonomously. Selective activation of intestinal Lxrα holds therapeutic promise.
28536535	8	18	Intestinal	T023	C0021853
28536535	19	23	LXRα	T116,T192	C0297439
28536535	27	37	Regulating	T038	C1327622
28536535	38	51	Post-prandial	T079	C0376674
28536535	52	57	Lipid	T109	C0023779
28536535	58	67	Excursion	T058	C3468074
28536535	72	76	Diet	T168	C0012155
28536535	79	86	Induced	T169	C0205263
28536535	87	107	Hypercholesterolemia	T047	C0020443
28536535	112	119	Hepatic	T029	C0205054
28536535	120	138	Lipid Accumulation	T033	C0333574
28536535	139	152	Post-prandial	T079	C0376674
28536535	153	167	hyperlipidemia	T047	C0020473
28536535	185	199	cardiovascular	T029	C3887460
28536535	200	211	risk factor	T033	C0035648
28536535	225	244	therapeutic options	T061	C0683525
28536535	250	267	Liver X receptors	T116,T192	C4277606
28536535	269	273	Lxrs	T116,T192	C4277606
28536535	279	304	nuclear hormone receptors	T116,T192	C0887829
28536535	310	318	regulate	T038	C1327622
28536535	319	330	cholesterol	T109,T123	C0008377
28536535	331	342	elimination	T039	C0221102
28536535	371	381	regulating	T038	C1327622
28536535	386	396	absorption	T039	C0443214
28536535	401	409	handling	T033	C1832073
28536535	413	425	dietary fats	T109,T168	C0012171
28536535	429	439	incomplete	T080	C0205257
28536535	496	506	intestinal	T023	C0021853
28536535	507	511	Lxrα	T116,T192	C0297439
28536535	515	528	post-prandial	T079	C0376674
28536535	529	539	intestinal	T023	C0021853
28536535	540	545	lipid	T109	C0023779
28536535	546	555	transport	T043	C0005528
28536535	563	567	Lxrα	T028	C1417824
28536535	568	576	knockout	T050	C1522225
28536535	578	588	nr1h3(-/-)	T028	C1417824
28536535	594	603	intestine	T023	C0021853
28536535	606	613	limited	T169	C0439801
28536535	614	618	Lxrα	T028	C1417824
28536535	619	634	over-expressing	T045	C0017262
28536535	639	645	fabp2a	T028	C1333525
28536535	647	651	EGFP	T028	C0017337
28536535	654	659	nr1h3	T028	C1417824
28536535	662	671	zebrafish	T013	C0043457
28536535	672	679	strains	T001	C1518614
28536535	693	706	post-prandial	T079	C0376674
28536535	707	712	lipid	T109	C0023779
28536535	713	722	excursion	T058	C3468074
28536535	728	740	live imaging	T060	C0011923
28536535	744	750	larvae	T204	C0023047
28536535	755	768	physiological	T169	C0205463
28536535	769	776	methods	T170	C0025663
28536535	780	786	adults	T008	C0596888
28536535	808	817	long-term	T079	C0443252
28536535	818	822	high	T080	C0205250
28536535	825	836	cholesterol	T109,T123	C0008377
28536535	837	844	dietary	T168	C0012155
28536535	845	854	challenge	T058	C0805586
28536535	858	864	adults	T008	C0596888
28536535	880	887	chronic	T079	C0205191
28536535	888	894	effect	T080	C1280500
28536535	909	919	nr1h3 gene	T028	C1417824
28536535	920	924	dose	T081	C0178602
28536535	932	943	development	T169	C1527148
28536535	947	967	hypercholesterolemia	T047	C0020443
28536535	972	979	hepatic	T029	C0205054
28536535	980	998	lipid accumulation	T033	C0333574
28536535	1000	1015	Over-expression	T045	C1171362
28536535	1019	1023	Lxrα	T028	C1417824
28536535	1031	1040	intestine	T023	C0021853
28536535	1041	1047	delays	T079	C0205421
28536535	1052	1061	transport	T043	C0005528
28536535	1074	1080	lipids	T109	C0023779
28536535	1084	1090	larvae	T204	C0023047
28536535	1098	1106	deletion	T045	C0017260
28536535	1110	1114	Lxrα	T116,T192	C0297439
28536535	1129	1133	rate	T081	C1521828
28536535	1137	1142	lipid	T109	C0023779
28536535	1143	1152	transport	T043	C0005528
28536535	1167	1175	wildtype	T028	C1883559
28536535	1176	1182	larvae	T204	C0023047
28536535	1206	1209	Lxr	T116,T192	C4277606
28536535	1210	1217	agonist	T121	C2987634
28536535	1218	1237	hyodeoxycholic acid	T109	C0063208
28536535	1243	1250	delayed	T079	C0205421
28536535	1255	1259	rate	T081	C1521828
28536535	1263	1273	intestinal	T023	C0021853
28536535	1274	1279	lipid	T109	C0023779
28536535	1280	1289	transport	T043	C0005528
28536535	1293	1299	larvae	T204	C0023047
28536535	1304	1309	adult	T008	C0596888
28536535	1310	1315	males	T032	C0086582
28536535	1317	1325	deletion	T045	C0017260
28536535	1329	1333	Lxrα	T028	C1417824
28536535	1334	1345	accelerates	T169	C0521110
28536535	1346	1356	intestinal	T023	C0021853
28536535	1357	1366	transport	T043	C0005528
28536535	1379	1385	lipids	T109	C0023779
28536535	1387	1392	Adult	T008	C0596888
28536535	1393	1400	females	T032	C0086287
28536535	1415	1421	plasma	T031	C0032105
28536535	1422	1440	Lipoprotein lipase	T116,T126	C0023816
28536535	1442	1445	Lpl	T116,T126	C0023816
28536535	1447	1455	activity	T044	C0243102
28536535	1468	1473	males	T032	C0086582
28536535	1485	1496	post-gavage	T079	C1254367
28536535	1497	1502	blood	T031	C0005767
28536535	1503	1518	triacylglycerol	T109,T123	C0041004
28536535	1520	1523	TAG	T109,T123	C0041004
28536535	1525	1534	excursion	T058	C3468074
28536535	1548	1573	sexually dimorphic effect	T032	C0036866
28536535	1583	1593	intestinal	T023	C0021853
28536535	1594	1599	lipid	T109	C0023779
28536535	1600	1608	handling	T033	C1832073
28536535	1613	1619	fabp2a	T028	C1333525
28536535	1621	1625	EGFP	T028	C0017337
28536535	1628	1633	nr1h3	T028	C1417824
28536535	1635	1641	adults	T008	C0596888
28536535	1650	1655	sexes	T032	C1522384
28536535	1675	1696	high cholesterol diet	T033	C2163356
28536535	1698	1701	HCD	T033	C2163356
28536535	1704	1711	induced	T169	C0205263
28536535	1712	1719	hepatic	T029	C0205054
28536535	1720	1738	lipid accumulation	T033	C0333574
28536535	1746	1756	nr1h3(-/-)	T028	C1417824
28536535	1757	1764	mutants	T049	C0596988
28536535	1769	1778	sensitive	T169	C0332324
28536535	1797	1800	HCD	T033	C2163356
28536535	1801	1810	challenge	T058	C0805586
28536535	1818	1822	data	T078	C1511726
28536535	1837	1847	intestinal	T023	C0021853
28536535	1848	1851	Lxr	T116,T192	C4277606
28536535	1852	1860	activity	T052	C0441655
28536535	1881	1891	intestinal	T023	C0021853
28536535	1892	1897	lipid	T109	C0023779
28536535	1898	1907	transport	T043	C0005528
28536535	1937	1947	activation	T052	C1879547
28536535	1951	1961	intestinal	T023	C0021853
28536535	1962	1966	Lxrα	T116,T192	C0297439
28536535	1973	1984	therapeutic	T169	C0302350